zoledronic acid has been researched along with su 11248 in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chow, E; Ehrlich, L; Hird, AE; Ko, YJ; Probyn, L; Sinclair, E; Yip, D | 1 |
| Ayllon, J; Cros, C; Launay-Vacher, V; Medioni, J; Oudard, S; Spano, JP | 1 |
| Bozas, G; Maraveyas, A; Ramasamy, V; Roy, A | 1 |
| Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
| Cagli, B; Intagliata, S; Onetti Muda, A; Perrone, G; Persichetti, P; Santini, D; Segreto, F; Tonini, G | 1 |
| Pazianas, M | 1 |
| Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E | 1 |
| Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Bahleda, R; Escudier, B; Gueutin, V; Izzedine, H; Rouvier, P; Soria, JC; Varga, A | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
| Bäuerle, T; Bendl, R; Bretschi, M; Fränzle, A; Hillengass, J; Merz, M; Semmler, W | 1 |
| Bedogni, A; Bettini, G; Bonacina, R; Campisi, G; Di Fede, O; Fusco, V; Guglielmini, P; Lo Re, G; Merigo, E; Paglino, C; Porta, C; Saia, G; Scoletta, M; Vescovi, P | 1 |
| Soós, B; Szalma, J; Vajta, L | 1 |
| Estilo, CL; Huryn, JM; Liang, STY; Owosho, AA; Sax, AZ; Wu, K; Yom, SK | 1 |
| Harada, H; Hosaka, S; Katagiri, H; Murata, H; Niwakawa, M; Takahashi, M; Wasa, J | 1 |
| Azambuja, AA; Cherubini, K; de Figueiredo, MAZ; Koth, VS; Ratzkowski, B; Salum, FG | 1 |
| Guo, CB; Guo, YX; Huang, HY; Li, QX; Qiao, Q; Wang, YF; Zhao, N | 1 |
4 review(s) available for zoledronic acid and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Indoles; Italy; Jaw; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2015 |
15 other study(ies) available for zoledronic acid and su 11248
| Article | Year |
|---|---|
Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pain Management; Palliative Care; Pyrroles; Quality of Life; Sunitinib; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
Topics: Angiogenesis Inhibitors; Diphosphonates; Humans; Imidazoles; Indoles; Jaw Diseases; Osteonecrosis; Pyrroles; Sunitinib; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Diphosphonates; Drug Synergism; Humans; Imidazoles; Indoles; Infusions, Intravenous; Kidney Neoplasms; Male; Mandibular Diseases; Middle Aged; Neoplasm Staging; Osteonecrosis; Pyrroles; Sacrum; Spinal Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Bone Neoplasms; Breast Neoplasms; Contrast Media; Diphosphonates; Humans; Imidazoles; Indoles; Longitudinal Studies; Magnetic Resonance Imaging; Pyrroles; Random Allocation; Rats; Rats, Nude; Sunitinib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Recurrent scrotal hemangiomas during treatment with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Genital Neoplasms, Male; Hemangioma; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Recurrence; Scrotum; Skin Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Renal Cell; Cisplatin; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Glutamates; Guanine; Humans; Imidazoles; Indoles; Interferons; Kidney Tubules; Lung Neoplasms; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Necrosis; Nephrectomy; Pemetrexed; Prednisone; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vincristine; Zoledronic Acid | 2013 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |
Assessing treatment response of osteolytic lesions by manual volumetry, automatic segmentation, and RECIST in experimental bone metastases.
Topics: Algorithms; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cone-Beam Computed Tomography; Diphosphonates; Disease Models, Animal; Follow-Up Studies; Imidazoles; Indoles; Pyrroles; Radiographic Image Interpretation, Computer-Assisted; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Zoledronic Acid | 2014 |
[Sunitinib and zoledronic acid induced osteonecrosis of the jaw].
Topics: Adult; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Indoles; Mandible; Oral Surgical Procedures; Osteonecrosis; Pyrroles; Sunitinib; Treatment Outcome; Zoledronic Acid | 2015 |
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Indoles; Ipilimumab; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2018 |
Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Chemoradiotherapy; Female; Fractures, Spontaneous; Humans; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies; Spinal Cord Compression; Sunitinib; Survival Rate; Treatment Outcome; Zoledronic Acid | 2018 |
Effect of tyrosine kinase inhibitor sunitinib on tissue repair at tooth extraction sites.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Rats; Rats, Wistar; Sunitinib; Tooth Extraction; Tyrosine Kinase Inhibitors; Zoledronic Acid | 2023 |
Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.
Topics: Angiogenesis Inhibitors; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Fibroblasts; Mice; Sunitinib; X-Ray Microtomography; Zoledronic Acid | 2023 |